Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients With Advanced Non-Small Cell Lung Cancer

NCT00456261 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.

NCT NCT00456261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00456261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients With Advanced Non-Small Cell Lung Cancer
Lead sponsor
SCRI Development Innovations, LLC
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2007
Completion date
September 30, 2012
Enrollment
110 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer